The Mycoplasma spp. ‘Releasome’: A New Concept for a Long-Known Phenomenon

Patrice Gaurivaud* and Florence Tardy
Anses, Laboratoire de Lyon, VetAgro Sup, UMR Mycoplasmoses Animales, Université de Lyon, Lyon, France

The bacterial secretome comprises polypeptides expressed at the cell surface or released into the extracellular environment as well as the corresponding secretion machineries. Despite their reduced coding capacities, Mycoplasma spp. are able to produce and release several components into their environment, including polypeptides, exopolysaccharides and extracellular vesicles. Technical difficulties in purifying these elements from the complex broth media used to grow mycoplasmas have recently been overcome by optimizing growth conditions and switching to chemically defined culture media. However, the secretion pathways responsible for the release of these structurally varied elements are still poorly described in mycoplasmas. We propose the use of the term ‘releasome,’ instead of secretome, to refer to molecules released by mycoplasmas into their environment. The aim of this review is to more precisely delineate the elements that should be considered part of the mycoplasmal releasome and their role in the interplay of mycoplasmas with host cells and tissues.

Keywords: secretome, polysaccharide, Mycoplasma, extracellular vesicles, exoproteome

INTRODUCTION

The term bacterial secretome was coined in the very beginning of the 21st century (Tjalsma et al., 2000) to describe “the components of machineries for protein secretion and the native secreted proteins,” with a primary focus on the secretion systems, i.e., machineries, involved in membrane translocation. Since then, the definition of the secretome has been regularly revised to focus more on the final localization of the secreted proteins and their potential distinct associated functions (Desvaux et al., 2009; Armengaud et al., 2012; Monteiro et al., 2021). The concept of the secretome now includes surface-exposed proteins (surface proteome), proteins released as free (not cell-attached) into the bacterial environment (exoproteome) and proteins embedded in extracellular vesicles (proteovesiculome) (Monteiro et al., 2021). The bacterial secretome plays a range of roles in interactions with the host (including adhesion, invasion, immune evasion and modulation), nutrient acquisition, and interactions between bacterial cells. Some of these interactions are positive, like biofilm formation, while others can be negative, like competition (Chagnot et al., 2013; Sharma et al., 2017; Tommassen and Arenas, 2017; Hernandez et al., 2020). Many of the proteins involved in virulence are found in the secretome, and characterizing these proteins is essential to understanding host-pathogen interactions and ultimately to developing a suitable disease control strategy (Dwivedi et al., 2016). However, although most of the extant literature has focused on secreted proteins, other polymers, like polysaccharides, are also exported by bacteria and fulfill different functions, depending on their final location, i.e., either cell-attached or not (Desvaux et al., 2009; Woodward and Naismith, 2016). Here we propose to (i) broaden the concept of the bacterial secretome to include non-polypeptide molecules like polysaccharides and...
more complex elements like extracellular vesicles (EV), and to (ii) rename this broader group of components releasome in order to take account of the gaps in knowledge about secretion machineries in some bacterial models (which is especially true for mycoplasmas) and to alter the focus exclusively to non-cell-attached elements released by living cells.

Polysaccharides are long-chain polymers composed of sugar units linked by glycosidic bonds. Extracellular polysaccharides either are attached to the cell and form a capsule or a slime layer around the cell, or are secreted as cell-free polysaccharides into the bacterium’s immediate environment. The generic term exopolysaccharides was proposed in 1972 to describe these two extracellular localizations (Sutherland, 1972). Many studies on exopolysaccharides fail to clearly specify their precise localization (free vs. cell-attached). However, it is essential to make a distinction between cell-linked and cell-free exopolysaccharides, as the two forms may play different roles in host interactions. The methodology used for purification provides clues about the type of exopolysaccharides under study: cell-linked polysaccharides are purified from washed cell pellets, while cell-free polysaccharides are purified from cell-free supernatants. In this review, for purposes of clarification, we use the acronym for cell-linked polysaccharides (CPS) that can form a capsule or a slime around the cell, and we use the term exopolysaccharides (EPS) strictly to refer to cell-free polysaccharides. The fact the composition and structure of the polysaccharide moiety might be identical with a single shared biosynthesis pathway (Woodward and Naismith, 2016) can make it difficult to distinguish between CPS and EPS: for instance, stresses can release CPS into the environment (Sutherland, 1985; Cerning, 1990; Llobet et al., 2008), and structures such as biofilms can make it difficult to assess cell attachment.

Extracellular vesicles are the most complex structures of the releasome, as they are composed of lipids, proteins, glycoconjugates and nucleic acids. Their composition reflects their biogenesis from the cell (Kim et al., 2015; Toyofuku et al., 2019). Bacterial EV are defined as non-replicative, membranous spherical structures with a size ranging from 20–400 nm that are secreted by viable cells (Deatherage et al., 2009; Toyofuku et al., 2019), and structures such as biofilms can make it difficult to assess cell attachment.

Figure 1 summarizes all potential components included in the releasome to date, i.e., a subset of polypeptides (whatever the secretion pathways) plus polysaccharides, EV, nucleic acids and metabolites (such as H₂O₂ or H₂S) released into the extracellular milieu. The releasome definition is particularly suitable for bacteria of the genus Mycoplasma, for which secretion systems are poorly known or poorly predictable in silico (Zubair et al., 2020a). Mycoplasmas, i.e., bacteria belonging to the genus Mycoplasma (M.), are small (300–800 nm diameter), wall-less bacteria with only a phospholipid, cholesterol-rich bilayer membrane surrounding the cytoplasm (Figure 1A, in contrast to panels B,C which show Gram+ or Gram− bacteria, respectively). Released molecules are ‘just’ translocated through the cytoplasmic membrane, which is a simpler situation than in the Gram+ and Gram− bacteria (Desvaux et al., 2009). Because of their small genome, coding for less than 1000 proteins, and the paucity of their metabolic pathways, mycoplasmas are considered the simplest bacteria able to replicate in an acellular medium (Razin et al., 1998). The first evidence of cell-free molecules released by mycoplasmas is historically related to the first culture (in 1898) of M. mycoides subsp. mycoides, the causal agent of contagious bovine pleuropneumonia (CBPP) (Nocard and Roux, 1898). The authors used a collodion bag containing broth inoculated with serous pulmonary fluid from a CBPP-diseased cow and placed into a peritoneal cavity of a rabbit. Mycoplasmas were able to survive and grow inside this non-permissive host because the collodion bag was permeable to host-released nutrients but offered protection against the rabbit immune system (Bove, 1999). Their work also found evidence that the collodion bag released a mycoplasma-produced component that induced necrosis in the surrounding tissues and might have contributed to cachexia in the rabbit (Lloyd, 1966). Other studies in the 1960s–1970s demonstrated some cell-free molecules released by mycoplasmas, such as polysaccharides or antigens recovered from the body fluids of CBPP-infected animals (Plackett et al., 1963; Gourlay, 1965), nanosized globular elements observed by microscopy in M. pneumoniae broth cultures (Eng and Froholm, 1971), and uncharacterized molecules that had cytotoxic activity in the supernatant of M. bovis genitalium cultures (Afshar, 1967). However, investigators at the time were unable to precisely identify the chemical structure of these elements, as they were unable to purify them from components of the complex growth medium or from body fluids. These experimental bottlenecks have recently been eased through various strategies that are covered in the first part of this review. In the second part, we propose an updated picture of the known composition and role of three main components of the releasome—exoproteins, EPS, and EV—in Mycoplasma spp. This concerns only components released into supernatants of mycoplasma growth medium alone or in interaction with host cells. Cellular invasion by mycoplasmas have been described for several species, including M. hyopneumoniae (Raymond et al., 2018b), M. bovis (Burki et al., 2015), M. genitalium (McGowin et al., 2009), M. fermentans (Yavlovich et al., 2004a), and M. pneumoniae (Yavlovich et al., 2004b) and the phenomenon is likely to be widespread. However, components released by mycoplasmas once in this cytoplasmic compartment of the host cell have not been studied thus far. Molecular mechanisms leading to the release of exoproteins, EPS and EV will not be covered here except for purpose of understanding the potential dual localization of molecules. The third and final section discusses the role of the mycoplasmal releasome.

**EXPERIMENTAL BOTTLENECKS TO CHARACTERIZING THE RELEASOME OF MYCOPLASMAS IN VITRO**

Molecules found free in a bacterial growth medium can have 3 distinct origins: (i) they could be brought by some complex components of the medium itself (such as serum, for instance), (ii) they could be released as a result of cell lysis during the different growth phases or purification processes, or (iii) they
could be actively secreted or “simply” released (in the absence of known secretion machineries) by the bacterium. The releasome corresponds to the third category only, and one of the main experimental difficulties is to distinguish this category from the two others. Interference from medium components and from non-specific release of mycoplasma components (due to cell lysis in the different growth phases or harsh purification processes) varies between the different classes of molecules (proteins, polysaccharides, membrane vesicles) and the methodology used for their characterization (Figure 2). Exoproteins are usually identified by mass spectrometry, exopolysaccharides are identified by HPLC and NMR, and EV are first observed by TEM, and their composition is characterized using various biochemical techniques. In vitro characterization of the releasome necessitates a fine balance between placing mycoplasmas in the conditions where they actually release components (whether or not related to the total biomass produced) and finding experimental conditions that enable detection or purification of these components from the culture supernatant. The composition of the culture medium, the growth time before harvest, and the potential interspecies or interstrain diversity also need to be considered, as they can substantially influence the composition of the releasome (Bertin et al., 2015; Monteiro et al., 2021; Olaya-Abril et al., 2021).

**Exoproteome**

Two recent papers have summarized the experimental bottlenecks and strategies for purification of the mycoplasmal exoproteome (Zubair et al., 2020a; Zhang et al., 2021). The authors pointed out that the high polypeptide concentrations in the growth media contributed by components such as serum dramatically jeopardizes the purification of proteins released by mycoplasmas, as is the case for exoproteins from eukaryotic cells that require serum for growth (Armengaud et al., 2012). Indeed, the 20% serum supplementation, usually used in mycoplasma medium, adds up to 12 g of proteins/L, which is dramatically more than the 2 mg of mycoplasma biomass/L reached by *M. hyopneumoniae* under optimized growth conditions (Hwang et al., 2010). A simple solution is to lower the relative concentrations of serum, as has been done to study the exoproteome of *M. hyopneumoniae/M. flocculare* (Paes et al., 2017) and *M. bovis* (Zubair et al., 2020b). However, such modifications of the growth medium dramatically affect the
growth of mycoplasmas (Paes et al., 2017; Zubair et al., 2020b). Another strategy is to employ an ultrafiltration process to remove polypeptides from the growth medium prior to use. Voros et al. assessed the exoproteome of M. capricolum subsp. capricolum grown in a 10 kDa filtered complex medium (Voros et al., 2015). This process depletes proteins with a molecular weight greater than 10 kDa, but it comes at a risk of also removing lipids and cholesterol, which are essential for mycoplasma growth. However, the ultra-filtered medium nevertheless allowed residual growth of M. capricolum subsp. capricolum (Voros et al., 2009). Another method for bypassing this problem is to use a two-step approach (Figure 2), i.e., first, to produce a reasonable quantity of viable mycoplasma cells using complex growth media, and then to transfer the cells into a chemically defined medium with a reduced protein concentration (Ganter et al., 2019) or in an isotonic buffer like PBS (Zhang et al., 2021). Transferring mycoplasmas from a complex to a simpler medium requires centrifugation and washing steps that are associated with a risk of cell lysis and consequently release of cytoplasmic proteins. In a medium allowing growth (complete or serum-reduced), mycoplasmas can be harvested during the log phase, assuming that no cell lysis occurs. When mycoplasmas are incubated in a medium other than those allowing growth, the viability of the mycoplasmas over the incubation time needs to be checked, for instance by plating aliquots onto solid media and counting colonies (Ganter et al., 2019; Zhang et al., 2021; Figure 2).

Centrifugation of mycoplasma cells is an essential step in the process of purifying exoproteins from the broth supernatant (Figure 2). However, even at 15000 g, viable mycoplasmas may remain in the supernatant (Hopfe et al., 2004). Increasing centrifuge force to completely remove floating cells (Zubair et al., 2020b) might not be the best solution, as it could damage the cells.
and result in cell lysis (Razin et al., 1973). A preferred solution would be to filter the supernatant through a 0.1-µm filter before characterizing the exoproteome. While 0.2-µm filters can stop mycoplasma cells they do not completely remove all mycoplasma species (Gaurivaud et al., 2018). An agar plate count of viable mycoplasmas remaining in the supernatant is an easily performed control, but ensuring the total absence of viable mycoplasma cells is highly dependent on the test sample seeded on the agar plate. The control of potential cell lysis during purification could be ensured by detecting cytoplasmic or membrane proteins in supernatants using antibodies or assays for cytoplasmic enzymes such as lactate dehydrogenase (Voros et al., 2015) or hexokinase (Minion et al., 1993). However, caution is warranted when interpreting the results, as some moonlighting proteins expected to be cytoplasmic or membrane-bound can also be released into the extracellular environment as discussed below. For the same reason, the extracellular localization of a specific protein needs to be double-checked to confidently exclude any contamination by cell proteins during the exoproteome purification process. Protein localization is done either by detecting their enzymatic activities if feasible (e.g., extracellular nucleases; (Yamamoto et al., 2017)), or by using specific antibodies (Djordjevic et al., 2004; Zhang et al., 2016; Li et al., 2019). Such tests can be performed directly in complex medium and are less influenced by the contamination from cell lysis associated with transfer to a defined medium.

Exopolysaccharides

As with the exoproteome, a complex growth medium is not suitable for mycoplasmal EPS purification (Bertin et al., 2013). Serum and yeast extracts contained in the growth medium contribute high concentrations of exogenous polysaccharides that hamper purification of the mycoplasmal polysaccharides. Because very low quantities of EPS are produced by mycoplasmas [a maximum of 50 mg/L for M. mycoides subsp. mycoides (Bertin et al., 2013), while Klebsiella or Acinetobacter spp. can produce up to 6 g/L (Bryan et al., 1986)], partial depletion of exogenous polysaccharides is not sufficient, so the alternative is to use a defined culture medium that is totally devoid of polysaccharides. The effort to develop serum-free defined media started in the 1960s (Tourrellotte et al., 1964) with the aim of determining mycoplasma nutrient requirements more precisely (e.g., preferred carbon sources) and studying their general metabolism (e.g., sugar biosynthesis pathways; (Yus et al., 2009; Jordan et al., 2013)). However, although defined culture media enable control of substrate concentrations, they remain difficult to produce and use even today, and have not been optimized for all mycoplasma species. A simpler alternative consists of using serum-free eukaryotic cell culture media such as CMRL, which contains only glucose as a carbon source—a strategy we previously used to purify polysaccharides secreted by mycoplasmas belonging to the M. mycoides cluster (Bertin et al., 2013, 2015) and by M. agalactiae (Gaurivaud et al., 2016). In culture media used for eukaryotic cell growth, mycoplasmas may maintain a degree of viability, but are unable to grow. Therefore, to reach a satisfactory biomass, mycoplasmas have to be first grown in a complex medium, with cells pelleted and washed before being transferred into the defined eukaryotic cell medium (Figure 2). During incubation in CMRL, mycoplasmas remain viable and metabolically active for a period of time, with the duration dependent on the species. Polysaccharides are produced by viable mycoplasmal cells, and so a viability time-course has to be checked before purification of the polysaccharides (Figure 2). However, even if some mycoplasmas are lysed in the process, this does not result in non-specific release of CPS (Bertin et al., 2013). After incubation, mycoplasma cells are removed by centrifugation. A supplementary 0.1-µm filtration step is not essential, as the remaining cells and proteins in the supernatant are removed by trichloracetic acid precipitation (Figure 2). Finally, the polysaccharides are precipitated with acetone or ethanol. The level of purification can be increased by adding a further step, such as dialysis, to remove free hexoses, which interfere with the sugar composition measured by HPLC, and phenol treatment to remove biologically active small peptides (Totte et al., 2015).

Antibodies raised against polysaccharides are a good screening tool to help track the purification process or detect EPS in biological fluids (Bertin et al., 2015). However, they are not easily produced, as large amounts of purified polysaccharides conjugated to a carrier protein are required.

Extracellular Vesicles

The ultracentrifugation step necessary to collect EV produced in a complex growth medium often results in an unwanted non-specific adsorption of albumin and immunoglobulins from the serum onto the surface of the vesicles, thus jeopardizing purification. The same difficulties are met during purification of exosomes from blood (Caradec et al., 2014). Reducing the serum and yeast extract concentrations is a good option, as it limits this ‘co-purification’ and also induces a nutritional stress conducive to vesicles formation and shedding (Klimentova and Stulik, 2015). This approach has been used for EV purification from Mycoplasma spp. and species of another close genus also belonging to the class Mollicutes, Acholeplasma (Chernov et al., 2011; Gaurivaud et al., 2018; Figure 2). Other stresses favoring EV production might be considered, such as iron deprivation through the use of chelators (Madsen et al., 2006; Martinez-Torro et al., 2020). Serum contains eukaryotic membrane vesicles that have to be removed before preparing the growth medium in order to ensure they are not co-purified with the EV (Kornilov et al., 2018). In vitro, EV are only produced by viable mycoplasma cells, and we demonstrated previously that lysed, heat-killed cells do not produce non-specific EV-like vesicles (Gaurivaud et al., 2018). A viability control is therefore necessary during experiments to produce EV.

Before ultracentrifugation of the broth medium supernatant to collect the EV, a preliminary 0.1-µm filtration is advisable to remove small mycoplasma cells that could still be in suspension after elimination of the pelleted cells (Figure 2). However, this filtration step could also remove some of the large vesicles and hence select a sub-population of EV (Konoshenko et al., 2018), as there is a clear size overlap between small cells and larges vesicles (Gaurivaud et al., 2018).
Once pelleted, EV can be further purified using density gradients (sucrose, Optiprep™) or chromatography, as described for Gram-positive and Gram-negative bacterial vesicles (Kim et al., 2015; Klimentova and Stulik, 2015). This supplementary purification step has already been validated for Acholoplasma laidlawii (Chernov et al., 2014) and could be used for Mycoplasma spp., where it would help to remove any residual mycoplasma cells that might interfere with characterization of the polypeptides (by MS) and the DNA content (by PCR) of the purified EV.

**KNOWN ELEMENTS OF THE MYCOPLASMAL RELEASESOME**

**Exoproteome**

Mycoplasma exoproteomes have been a recent focus of research and these studies have benefited from the considerable developmental advances in other bacterial models (Zubair et al., 2020a). The first partial exoproteome was obtained in 2012 for M. synoviae (Rebollo Couto et al., 2012), followed by those of M. hyopneumoniae, M. flocculare, M. bovis and M. capricolum subsp. capricolum cultivated in axenic conditions (Voros et al., 2015; Paes et al., 2017; Zubair et al., 2020b; Zhang et al., 2021). Another study explored the exoproteome produced by swine mycoplasmas in interaction with their host cells (Leal Zimmer et al., 2019). However, relevant studies remain scarce and are not readily comparable because of the use of different methodological approaches (strains, culture conditions, purification steps). Because of these problems with comparability, we have focused only on exoproteins that have a specific, detectable function (Table 1).

**Nucleases**

Nucleases are easy to detect in vitro by visualization of DNA hydrolysis. For instance, DNA can be embedded into a solid matrix, either agar growth medium or a polyacrylamide gel, and its hydrolysis results in a clear halo around colonies or a clear band after electrophoretic migration of the nuclease (Minion et al., 1993; Sharma et al., 2015; Zhang et al., 2016; Yamamoto et al., 2017). Extracellular nucleases have been suspected in mycoplasmas since 1993, when Minion et al. demonstrated degradation of linear DNA by mycoplasma-free supernatants obtained after incubation of several mycoplasma species in a nuclease assay buffer (Minion et al., 1993). More recently, DNA degradation around M. pneumoniae colonies indicated the secretion of an extracellular nuclease, which was found by mutagenesis to be the MPN491 nuclease (Yamamoto et al., 2017). The inactivation/deletion of the gene coding MPN491 resulted in a reduced survival of M. pneumoniae in the presence of neutrophils in vitro as well as in vivo in a mouse nasal infection model. The most recent example, poor survival of a mutant was associated with its inability to degrade NETs induced by Escherichia coli lipopolysaccharides (Yamamoto et al., 2017).

Specific antibodies can be used to detect and localize nucleases. An example is the Mhp597 nuclease of M. hyopneumoniae, an ortholog of M. pneumoniae MPN491, which was detected in the growth medium supernatant by western blotting using specific antibodies (Li et al., 2019).

Although less straightforward, bulk proteomics data can be examined to detect potential nucleases in the cell environment. For instance, several nucleases have been identified by MS in the exoproteome purified from cell-free culture supernatants [e.g., Mhp7448_0580 (homolog of Mhp597) and MBOV_RS02825] or in the supernatant of a swine tracheal cell line infected with M. hyopneumoniae (Zhang et al., 2016; Paes et al., 2017; Leal Zimmer et al., 2019; Table 1).

Once secreted into the mycoplasmal environment, extracellular nucleases could participate in (i) nutrient scavenging (through degradation of the DNA released by cell lysis during the infection process) or in (ii) host evasion through hydrolysis of the neutrophil extracellular traps (NET), which are DNA networks produced by neutrophils that can trap and kill pathogens. NET evasion has been shown in vitro for two important lung pathogens, M. bovis in cattle (by nuclease MBOV_RS02825) and M. pneumoniae in humans (with nuclease MPN491) (Zhang et al., 2016; Yamamoto et al., 2017). The inactivation/deletion of the gene coding MPN491 resulted in a reduced survival of M. pneumoniae in the presence of neutrophils in vitro as well as in vivo in a mouse nasal infection model. In the most recent example, poor survival of a mutant was associated with its inability to degrade NETs induced by Escherichia coli lipopolysaccharides (Yamamoto et al., 2017).

**Proteases**

Extracellular proteases produced by lung-colonizing ruminant mycoplasmas have been demonstrated by measuring the degradation of fluorescent casein in culture supernatants and observing clearer digestion areas around colonies on casein-enriched solid medium (Allam et al., 2010; Ganter et al., 2019). Zymography and mutagenesis experiments further showed that M. mycoides subsp. capri MMCAP2_0241 and M. capricolum subsp. capricolum MCAP_0240, which both belong to the S41 peptidase family, are the main extracellular peptidases of these two species (Allam et al., 2010, 2012; Ganter et al., 2019). By zymography, the apparent molecular mass of these polypeptides was estimated to be 55 kDa, in contrast with the 75 kDa molecular mass predicted from the sequences of the corresponding genes. Two predicted transmembrane domains at the N- and C-terminal ends suggest a potential membrane localization of the native proteins that may be cleaved, by endoproteolysis for example, to be released into the medium (Ganter et al., 2019).

Sequence analysis and function prediction have identified several peptidases in the exoproteome of M. capricolum subsp. capricolum (Voros et al., 2015) and M. bovis (Zubair et al., 2020b), as well as in the supernatant of cells infected with M. hyopneumoniae and M. flocculare (Leal Zimmer et al., 2019; Table 1).

In other bacterial models, such as Staphylococcus (S.) aureus, extracellular proteases are involved in nutrient acquisition,
TABLE 1 | Non-exhaustive list of exoproteins with known functions released by *Mycoplasma* (sub)species.

| Proteins | Identification | Species | Strains | Mnemonic/accession number | Culture conditions | Detection in extracellular environment | References |
|----------|----------------|---------|---------|---------------------------|--------------------|----------------------------------------|------------|
| Nucleases | Ca$^{2+}$/Mg$^{2+}$ nuclease | *M. hyopneumoniae* | V11 | Mhp597 | Complete growth medium | Western blotting | Li et al., 2019 |
| | | 7448 | MHP7448_0580; MHU_0581 | | Serum reduced medium | Exoproteome | Paes et al., 2017 |
| | Endonuclease/exonuclease | *M. bovis* | HB0801 | MBOV_RS02825 | Complete growth medium | Western blotting | Leal Zimmer et al., 2019 |
| | | *M. pneumoniae* | M129 | MNP491 | Complete growth medium | Zymography | Yamamoto et al., 2017 |
| | Lipoprotein P40 | *M. penetrans* | GTU-54-6A1 | MYPE4380 | Complete growth medium | Zymography | Bendjennet et al., 1997 |
| | Superantigen | *M. arthritidis* | PG6 | Marth_orf036 | Complete growth medium | Lymphocytes proliferation | Atkin et al., 1994 |
| Peptidases | S41 family peptidase | *M. mycoides* subsp. capri | 95010 | MMCAP2_0241 | Complete growth medium | Casein hydrolysis | Ganter et al., 2019 |
| | | *M. capricolum* subsp. capricolum | Ckid | MCAP_0240 | Complete growth medium | Casein hydrolysis | Ganter et al., 2019 |
| | Putative peptidase DUF31 | *M. bovirhinis* | MV5 | MBVR141_0224 | Complete growth medium | Casein hydrolysis | Ganter et al., 2019 |
| | | *M. capricolum* subsp. capricolum | Ckid | MCAP_0193 | Serum reduced medium | Exoproteome | Voros et al., 2015 |
| | Oligoendopeptidase F | *M. hyopneumoniae* | 7448 | AAZ53887.2 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| | | *M. flocculare* | ATCC 27716 | ENX51111.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| | | *M. bovis* | HB0801 | Mbov_0133 | Serum reduced medium | Exoproteome | Zubair et al., 2020b |
| | | *M. capricolum* subsp. capricolum | Ckid | MCAP_0804 | Serum reduced medium | Exoproteome | Voros et al., 2015 |
| | Dipeptidase, putative | *M. capricolum* subsp. capricolum | Ckid | MCAP_0420 | Serum reduced medium | Exoproteome | Voros et al., 2015 |
| | Cytosol aminopeptidase | *M. capricolum* subsp. capricolum | Ckid | MCAP_0127; MCAP_0195 | Serum reduced medium | Exoproteome | Voros et al., 2015 |
| | Aminopeptidase | *M. flocculare* | ATCC 27716 | WP_002557776.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| | | *M. hyopneumoniae* | J | AAZ44217.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| | Leucyl aminopeptidase | *M. hyopneumoniae* | 7448 | AAZ53831.2 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| | | *M. flocculare* | ATCC 27716 | WP_002557977.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| | | *M. bovis* | HB0801 | Mbov_0789; Mbov_0673 | Serum reduced medium | Exoproteome | Zubair et al., 2020b |
| | XAA-PRO aminopeptidase | *M. hyopneumoniae* | 7448 | AAZ54021.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| | Peptidase M24 family protein | *M. flocculare* | ATCC 27716 | WP_002557496.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| | Clip protease ATP-binding subunit | *M. bovis* | HB0801 | Mbov_0703 | Serum reduced medium | Exoproteome | Zubair et al., 2020b |
| Lipases | Lipase MIA | *M. bovis* | PG45 | MBOVIPG45_0710 | Complete growth medium | Western blotting | Adamu et al., 2020 |
| | | | HB0801 | ADR24994.1 | Serum reduced medium | Exoproteome | Zubair et al., 2020b |
| | Lipase P65 | *M. hyopneumoniae* | 7448 | AAZ44018.1 | Serum reduced medium; Infected cells Exoproteome (serum free medium) | Exoproteome | Paes et al., 2017; Leal Zimmer et al., 2019 |
| | Triacyl glycerol lipase | *M. bovis* | HB0801 | Mbov_0558 | Serum reduced medium | Exoproteome | Zubi et al., 2020b |
| Adhesins | Protein P97 | *M. hyopneumoniae* | 7448 | MHP7448_0198; MHP7448_0108 | Serum reduced medium; Infected cells Exoproteome (serum free medium) | Paes et al., 2017; Leal Zimmer et al., 2019 |
| Proteins Identification | Species | Strains | Mnemonic/accession number | Culture conditions | Detection in extracellular environment | References |
|-------------------------|---------|---------|---------------------------|-------------------|---------------------------------------|------------|
| **Protein 102**         | M. hyopneumoniae | J AAZ44197.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| M. hyopneumoniae | 7448 | MHP7448_0199; MHP7448_0107 | Serum reduced medium; Infected cells (serum free medium) | Exoproteome | Paes et al., 2017; Leal Zimmer et al., 2019 |
| M. hyopneumoniae | J | AAZ44196.1; AAZ44286.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| M. hyopneumoniae | 232 | ND | Complete growth medium | Exoproteome | Immunoeloctron microscopy |
| M. flocculare | ATCC 27716 | MFC_00475 | Serum reduced medium | Exoproteome | Paes et al., 2017 |
| P216 surface protein | M. hyopneumoniae | 7448 | AAZ53862.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| M. hyopneumoniae | J | AAZ11196.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| ABC transporter xylose-binding lipoprotein | M. hyopneumoniae | 7448 | MHP7448_0604 | Serum reduced medium; Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| M. flocculare | ATCC 27716 | ENX51036.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| M. hyopneumoniae | J | AAZ44690.2 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| 46K surface antigen precursor | M. hyopneumoniae | 7448 | AAZ53879.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| M. flocculare | ATCC 27716 | WP_002557638.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| Others proteins | Pyruvate dehydrogenase E1, beta subunit | M. synoviae | 53 | gi| 1144575045 | Buffer | Exoproteome | Rebollo Couto et al., 2012 |
| M. hyopneumoniae | J | AAZ44204.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| M. synoviae | 53 | gi| 71894034 | Buffer | Exoproteome | Rebollo Couto et al., 2012 |
| M. capricolum subsp. capricolum | Kid | MCAK_0213 | Serum reduced medium | Exoproteome | Voros et al., 2015 |
| M. hyopneumoniae | 7448 | AAZ53624.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| M. flocculare | ATCC 27716 | WP_002557541.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| M. bovis | HB081 | Mbov_0482 | Serum reduced medium | Exoproteome | Leal Zimmer et al., 2019 |
| Chaperone protein DnaK | M. synoviae | 53 | gi| 71894366 | Buffer | Exoproteome | Rebollo Couto et al., 2012 |
| M. synoviae | 53 | gi| 71894344 | Buffer | Exoproteome | Leal Zimmer et al., 2019 |
| M. flocculare | ATCC 27716 | WP_002557592.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| M. bovis | HB081 | Mbov_ref| Serum reduced medium | Western blotting | Zhao et al., 2021 |
| Elongation factor EF-Tu | M. synoviae | 53 | gi| 71894677 | Buffer | Exoproteome | Rebollo Couto et al., 2012 |
| M. hyopneumoniae | 7448 | AAZ53889.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| M. flocculare | ATCC 27716 | WP_002557626.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| Lipoprotein P280 | M. bovis | HB081 | AFM51649.1 | Complete growth medium | Western blotting | Zhao et al., 2021 |
| M. hyopneumoniae | J | AAZ44125.1 | Infected cells (serum free medium) | Exoproteome | Leal Zimmer et al., 2019 |
| M. flocculare | ATCC 27716 | MFC_00829 | Serum reduced medium | Exoproteome | Paes et al., 2017 |
bacterial dissemination and immune evasion (Tam and Torres, 2019). In mycoplasmas, their precise roles have yet to be defined, with a few exceptions. For instance, in \textit{M. hyopneumoniae} the endopeptidase F and the XAA-pro aminopeptidase degrade immunologically active peptides (see below), and the cell-free form of aminopeptidase AAZ44217.1 is involved in adhesion to plasminogen and heparin (Robinson et al., 2013). Extracellular peptidases of \textit{M. capricolum} subsp. \textit{capricolum} MCAP_0240 may have a direct or indirect role in cell surface shaving and thus modulate adhesion and immune invasion, as deletion mutants had a modified surface proteome (Ganter et al., 2019).

**Lipases**

Chromogenic substrates, such as 2-naphthyl caprylate and 2-naphthyl butyrate, have made it possible to detect lipase activity in the supernatant of \textit{M. capricolum} subsp. \textit{capricolum} cultures (Voros et al., 2015), but the corresponding protein has not yet been identified. Lipase activity has also been detected in two immunodominant surface proteins, the P65 lipoprotein of \textit{M. hyopneumoniae} (Schmidt et al., 2004) and the \textit{M. bovis} MilA protein (Wawegama et al., 2014), using assays based on hydrolysis of lipid substrates such as O-dilauryl-rac-glycero-3-glutaric acid resorufin ester, \textit{p}-nitrophenyl caproate or \textit{p}-nitrophenyl palmitate. Western blotting further demonstrated that one of them, the \textit{M. bovis} MilA lipase, is released into the culture supernatant (Adamu et al., 2020) and it has also been found in the exoproteome of \textit{M. bovis} strain HB80801 (Zubair et al., 2020b).

In contrast, the P65 lipase of \textit{M. hyopneumoniae} was not directly shown to be extracellular, but has been found in the exoproteomes of \textit{M. hyopneumoniae} strains J and 7448 obtained from culture supernatants (Paes et al., 2017) and from the supernatant of infected cells (Leal Zimmer et al., 2019; Table 1).

In other bacteria, such as \textit{S. aureus}, secreted extracellular lipases are involved in a broad spectrum of functions, including acquisition of lipids from the host (Delektka et al., 2018), immune evasion (Chen and Alonzo, 2019), biofilm formation, and host cell invasion (Nguyen et al., 2018). The dual potential localization—i.e., extracellular as well as cell-attached—of MilA in mycoplasmas complicates research into its function(s) (Adamu et al., 2020). MilA seems to be essential, as \textit{M. bovis} growth is inhibited by anti-MilA antibodies, and screening of \textit{M. bovis} transposon libraries has failed to detect a MilA mutant (Sharma et al., 2014; Josi et al., 2019; Adamu et al., 2020). Cell-free recombinant MilA has been shown to bind lipid and heparin, suggesting a putative role in the processing and transport of lipids and in adhesion to the extracellular matrix (Adamu et al., 2020).

**Adhesins**

Dozens of mycoplasma proteins have the capacity to bind to host cells or to components of the host extracellular matrix such as actin, fibronectin and glycosaminoglycans. Several of these adhesins or adhesion-related proteins, although classically described as cell surface-associated (and belonging to the surfaceome), are regularly identified in the exoproteome of several mycoplasma species (Table 1). For instance, the P102 adhesin of \textit{M. hyopneumoniae} has been shown, by immunoelectron microscopy after experimental infection of swine, to be localized either within mycoplasma cells or distant from them and directly attached to respiratory cilia of the experimentally infected swine (Djordjevic et al., 2004; Adams et al., 2005). P102-homologs have been identified in the exoproteomes of \textit{M. hyopneumoniae} and \textit{M. flocculare} (Paes et al., 2017; Leal Zimmer et al., 2019; Table 1). Other adhesins have been found in the exoproteome of \textit{M. hyopneumoniae}, \textit{M. flocculare} and \textit{M. synoviae}, but no role has yet been firmly defined for them as released proteins (Table 1). A reasonable hypothesis could be that the release of adhesins from the mycoplasma cell could promote mycoplasma dispersion by limiting their adhesion to host cells and tissues, as described for other bacteria (Coutte et al., 2003). They could also be blocking anti-adhesin antibody binding to the cell, but this has yet to be demonstrated.

However, it is becoming increasingly evident that adhesins and other proteins could also play a role in degradation of the host extracellular matrix (ECM) by binding to plasminogen. This is the case for \textit{M. hyopneumoniae} adhesin P102 (Seymour et al., 2012; Leal Zimmer et al., 2020). Binding of P102 to plasminogen resulted in increased conversion of plasminogen into plasmin, a serine protease able to degrade the ECM either directly or through activation of other enzymes, such as metalloproteases (Seymour et al., 2012). This strategy of ECM degradation by subversion of the host plasmin system is used by many other bacteria to invade and spread (Lahteenmaki et al., 2005). Non-adhesin proteins that could also contribute to degradation of the ECM include the glycolytic enzyme glyceraldehyde-3-P-dehydrogenase (GAPDH) in \textit{M. hyorhinis} (Wang et al., 2021), the chaperone protein DNAK, GAPDH and subunit Ela of the pyruvate dehydrogenase complex (PDBH), another enzyme involved in carbon metabolism, in \textit{M. pneumoniae} (Grundel et al., 2016; Hagermann et al., 2017), the enzyme enolase, which catalyzes the interconversion of phosphoenolpyruvate into 2-phosphoglycerate in \textit{M. bovis} (Song et al., 2012), and the elongation factor EF-Tu, which orchestrates transport of aminoacylated tRNA to the ribosome, in \textit{M. pneumoniae} and \textit{M. hyopneumoniae} (Widjaja et al., 2017). These proteins have been found in the exoproteome of mycoplasmas (Table 1).

**Disruptors of Host-Cell Metabolism**

The cell-free form of the chaperone protein DnaK from \textit{M. fermentans} was also shown to be taken up by the host cells and localize in the cytoplasm, the perinuclear space and the nucleus (Benedetti et al., 2020). Once in the cell, DnaK interacts with several host proteins, including those involved in DNA repair, like PARP1 (poly-ADP ribose polymerase-1) and USP10 (ubiquitin carboxyl-terminal hydrolase protein-10). The interaction with USP10 in turn leads to a reduction in P53 activity, which is known to have an anti-oncogenic effect (Zella et al., 2018; Benedetti et al., 2020). For bacteria, this is a way to redirect host-cell metabolism to facilitate bacterial growth (Siegl and Rudel, 2015). Using immunoprecipitation techniques with an anti-P53 monoclonal antibody, Zella et al. identified other mycoplasmal proteins able to interact with P53, one of which was...
the glycolytic enzyme enolase (Zella et al., 2018), which has been found in the exoproteome of five mycoplasma species (Table 1).

**Modulators of Host Immune Response**

A western blotting study recently confirmed that the MbovP280 protein, predicted in silico to be secreted, was effectively released by *M. bovis* cells cultured for 36 h (Zhao et al., 2021). The secreted MbovP280 protein was further shown to bind to and induce the apoptosis of bovine macrophages through a complex signaling pathway (Zhao et al., 2021). However, the effect of a recombinant protein was greater than that of whole cells expressing MbovP280. Apoptotic activity has also been described for mycoplasmal extracellular proteins with other main roles. For instance, the nucleases P40 in *M. penetrans*, Mhp597 in *M. hyopneumoniae* and RS_02825 in *M. bovis* induce apoptosis in human lymphocytes (Bendjennat et al., 1999), in swine kidney epithelial cells (Li et al., 2019), and in bovine macrophages via the NFkB p65 pathway (Zhang et al., 2016), respectively. Extracellular nucleases can also play a role in modulation of cytokine production. *M. hyopneumoniae* Mhp597 nuclease has been shown to suppress INFγ secretion and stimulate IL1, IL8 and TNF secretion in macrophages (Li et al., 2019). This is an important finding, as INFγ is a first-line protection against viral infection. The MAM superantigen of *M. arthritidis* has also been shown to modulate cytokine release (Mu et al., 2000). In addition to nucleases, some proteases may also have immunomodulatory effects. *M. hyopneumoniae* endopeptidase F and XAA pro-aminopeptidase, which are both found in the exoproteome (Table 1), have recently been shown to be involved in the degradation of peptides that play a role in innate immunity (Jarocki et al., 2019). These data have started to demonstrate a role of the mycoplasmal releasome in evasion of the immune system and modulation of its activity, which are two important features of mycoplasmal virulence (Leal Zimmer et al., 2020; Askar et al., 2021; Jiang et al., 2021; Yiwen et al., 2021).

**Gaps and Perspectives**

The combination of (i) numerous potential experimental biases (failure to pellet some mycoplasma cells, cell lysis during the purification protocol, and so on), (ii) the high proportion (circa 30%) of hypothetical proteins with no associated function found in exoproteomes, (iii) the extent of moonlighting activity in mycoplasmal proteins, and (iv) underpowered in silico prediction capacity (Zhao et al., 2021) means that further studies complementary to studies characterizing the core exoproteome are necessary to confirm the extracellular localization of the exoproteins and decipher their role. With the growing interest in mycoplasmal exoproteins, the mycoplasmology community would welcome a consensus methodology guideline to improve the quality of results and enable valuable comparisons of exoproteomes between species. For instance, specific labeling of newly synthesized proteins using new methodologies such as bioorthogonal non-canonical amino acid tagging and proximity labeling (Shin et al., 2019; Sukumaran et al., 2021) could be helpful to distinguish the exoproteome of mycoplasmas from proteins contained in a complex environment. This includes complex growth medium, the cytoplasmic compartment in case of intracellular mycoplasmas, or different host sites occupied by mycoplasmas in the course of infection [for example *M. hyopneumoniae* has been detected in the heart, kidneys, liver and spleen of pigs (Le Carrou et al., 2006; Marois et al., 2007; Woolley et al., 2012)].

Studies addressing the role of exoproteins in the interplay with the host are also essential. As the generation and use of mycoplasma mutants is still limited, approaches based on recombinant proteins are increasingly being used (Bendjennat et al., 1999; Zhang et al., 2016; Yamamoto et al., 2017; Zhao et al., 2021), but they can sometimes exaggerate the actual role of a protein because of the high concentrations tested, which do not correspond to the actual quantities secreted by the cell (Zhao et al., 2021).

The mycoplasmology community is starting to gain a global picture of the role of exoproteome interactions with host cells and with components of the host extracellular matrix and how it shapes immune evasion or modulation. However, the exoproteome composition is likely to vary over time, depending on the host context and the time since infection. Variability in exoproteome composition between species, and potentially between strains, might also explain some of the variability in virulence.

Last but not least, although some Sec genes have been identified in silico (Staats et al., 2007), further investigation is needed into the mechanisms involved in protein release by *Mycoplasma* spp. For instance, surface shaving via proteases could contribute to the release of exoproteins from the cell-surface, highlighting the tight connection between the surfaceome and the releasome (Raymond et al., 2013; Jarocki et al., 2015, 2019; Tacchi et al., 2016; Berry et al., 2017; Ganter et al., 2019; Machado et al., 2020). Other non-classical protein release mechanisms have been suggested such as explosive cell events or ghost cells formation (Raymond et al., 2018a). Those could contribute to free into the extracellular medium membrane or cytoplasmic proteins (Wang et al., 2013).

**Exopolysaccharides**

**Composition and Structure**

Mycoplasma exopolysaccharides were first reported in the 1930s, when Kurotchkin described a carbohydrate released by *M. mycoides* subsp. *mycoides* into the culture medium and the blood of animals with acute CBPP (Kurotchkin, 1937; Kurotchkin and Benaradsky, 1938). It was then of unknown composition and structure, but cross-reacted serologically with the *M. mycoides* subsp. *mycoides* capsular polysaccharide (Plackett et al., 1963), which is composed of galactose and named galactan (Plackett and Buttery, 1958). By the 1960s, it was clear that *M. mycoides* subsp. *mycoides* produced both a CPS and an EPS, with a shared antigenic signature recognized by the same antibodies. Despite several efforts, purification of the EPS from culture supernatants remained thwarted by difficulties in eliminating contamination from polysaccharides, such as glycogen, contained in the growth medium (Plackett et al., 1963; Hudson et al., 1967). It was only in 2013 that Bertin et al. eliminated contamination with medium-associated polysaccharides by transferring PPLO-grown
**M. mycoides** subsp. *mycoides* cells into CMRL, a defined cell culture medium with no polysaccharides and only glucose as a carbon source (Bertin et al., 2013). CMRL was shown to sustain mycoplasmal metabolism but not growth (Bertin et al., 2013). An EPS, in free form in the spent CMRL, was purified and its composition and structure were shown by NMR and HPLC to be identical to the polysaccharide moiety of the capsular galactan described 50 years earlier (Bertin et al., 2013). This identity explained the immunological cross-reactivity between the EPS and CPS, but was limited to the polysaccharide moiety, as galactan CPS contains a lipid anchor (Buttery and Plackett, 1960) that is not present when the galactan is released from the cells (Bertin et al., 2013).

Other EPS were identified among the members of the *M. mycoides* cluster using the same purification method: a β-(1→2)-glucopyranose was detected in the culture supernatant of *M. capricolum* subsp. *capricolum*, *M. capricolum* subsp. *capripneumoniae* and *M. leachii* (Bertin et al., 2015; Table 2), and weak exopolysaccharide release was detected in vitro from the two serovars of *M. mycoides* subsp. *capri* (Bertin et al., 2015; Gaurivaud et al., 2016). Interestingly, the two serovars of the goat pathogen *M. mycoides* subsp. *capri* secreted two different polysaccharides: serovar LC (large colony) produced galactan and serovar capri produced β-(1→6)-glucopyranose. Both EPS were homopolysaccharides with no ramifications and no chemical modifications. However, not all mycoplasmal polysaccharides are as simple. The EPS isolated from *M. pneumoniae* biofilms, for instance, is composed of galactose and N-acetyl glucosamine (Simmons et al., 2013; Table 2).

All these EPS were also detected as CPS (Table 2). However, the presence of a CPS does not guarantee secretion of the corresponding EPS, as shown by the β-(1→6)-glucopyranose of *M. agalactiae*, which was only detected as a CPS (Gaurivaud et al., 2016; Table 2). Other EPS have been detected in *M. feriruminatoris*, which is able to produce a galactan and a β-(1→6)-glucopyranose CPS (Ambroset et al., 2017), and in *M. genitalium* (Daubenspeck et al., 2020) and *M. pulmonis* (Daubenspeck et al., 2009; Table 2). However, their release as EPS has not been demonstrated to date.

**Exopolysaccharides Biosynthesis**

In *M. mycoides* subsp. *mycoides*, the galactan is not secreted concomitantly as CPS and EPS in vitro, but rather alternatively by phenotypic variants undergoing phase variation (Bertin et al., 2013). One variant secreted a galactan CPS but no EPS, whereas the other one was not capsulated but produced a galactan EPS. This phenomenon was reversible and was shown to be related to the expression of a permease of the glucose-phosphoenolpyruvate phosphotransferase system (PTS) undergoing on/off phase variation (Gaurivaud et al., 2004; Bertin et al., 2013). The PTS system is a well-established sugar transport system, but also regulates carbon metabolism in bacteria (Deutscher et al., 2014) and has already been shown to regulate polysaccharide synthesis in *Vibrio cholerae* (Houot et al., 2010). One group posited glucose PTS system-mediated regulation of a glycosyltransferase possibly involved in attachment of the polysaccharide moiety to the membrane lipid anchor (Bertin et al., 2013), but the regulatory and attachment mechanisms have yet to be demonstrated.

A complete biosynthesis pathway involving a membrane glycosyltransferase belonging to the synthase family (Whitney and Howell, 2013), and catalyzing both polymerization and transfer of the galactan of *M. mycoides* subsp. *mycoides* in its CPS or EPS across the cytoplasmic membrane, has been proposed based on *in silico* data (Bertin et al., 2013). The role of synthases in mycoplasmal polysaccharide synthesis was also demonstrated using a functional genomics approach for the synthesis of the *M. agalactiae* β-(1→6)-glucopyranose (Gaurivaud et al., 2016). Among the many glycosyltransferases identified in mycoplasmal genomes, synthases are easily identified as they have 4 or 7 glycosyltransferase-active sites (Gaurivaud et al., 2016). The number of transmembrane domains may be linked to substrate specificity and the structure of the resulting polymer. Synthases have been predicted *in silico* for 14 *Mycoplasma* species, which suggests that several other polysaccharides have yet to be identified (Gaurivaud et al., 2016). In contrast, no synthesis pathway has been identified for the polysaccharides produced by *M. pulmonis*, *M. genitalium* or *M. pneumoniae* (Daubenspeck et al., 2009, 2020). However, an ABC transporter pathway (Schmid, 2018) has been suggested for *M. pulmonis*, as the mutation of two ABC permease genes was associated with a loss of polysaccharide production (Daubenspeck et al., 2009).

**Role in Host Interactions**

In mycoplasmas, as in other bacterial models, CPS are known to be involved in the modulation of cytoadherence (Bolland and Dybvig, 2012) and in protection against phagocytosis (Shaw et al., 2013) and against the bactericidal activity of the complement system (Bolland et al., 2012; Gaurivaud et al., 2014). In contrast, with the exception of circulating galactan in the body fluids of animals experiencing CBPP, the role of mycoplasmal EPS has been under-researched. Intravenous injection of galactan purified from *M. mycoides* subsp. *mycoides* culture supernatant into calves resulted in an increase of pulmonary arterial blood pressure and a transient apnea (Buttery et al., 1976). However, in its EPS form, the galactan did not induce any fever and did not affect the susceptibility of calves to subsequent subcutaneous infection with *M. mycoides* subsp. *mycoides* (Hudson et al., 1967; Buttery et al., 1976). However, these results need to be interpreted with caution, as the purified galactan was shown to contain peptides (Hudson et al., 1967; Buttery et al., 1976). This ambiguity was overcome recently by Totte et al. (2015) who used a high-purity-grade galactan obtained from *M. mycoides* subsp. *mycoides* supernatant, checked by SDS PAGE and NMR, to examine its effect on immune cells. Pure galactan failed to activate naive lymphocytes but induced IL-10 release by bovine macrophages, thus echoing the observation of peak IL-10 1–2 weeks after experimental infection of cattle with *M. mycoides* subsp. *mycoides* (Sacchini et al., 2012). Moreover, the purified free galactan was able to reduce the release of pro-inflammatory cytokines by macrophages in response to *Escherichia coli* lipopolysaccharide (Totte et al., 2015). These observations indicated that, overall, the galactan EPS acts as...
an immunosuppressor by inhibiting pro-inflammatory cytokines and increasing the IL-10 secretion that depresses T-cell responses (Totte et al., 2015).

Polysaccharides are a major constituent of biofilm matrices, where they play roles in binding different components and in physical resistance to stress or stratification of the biofilm structure (Limoli et al., 2015). Both CPS and EPS could contribute to biofilm formation in mycoplasmas. For instance, in *M. pulmonis*, different types of expressed dominant polysaccharides changed the propensity of strains to form a biofilm (Daubenspeck et al., 2009). Similarly, in *M. pneumoniae*, the volume, texture, robustness and internal structure of the biofilm was shown to differ between two strains (of different type), depending on how loosely or tightly the polysaccharides were attached to the mycoplasma cell (Simmons et al., 2013). This could ultimately completely modify the role of the resulting biofilm in virulence and chronicity of infection.

**Gaps and Perspectives**

Although extracellular polysaccharides have been detected in several *Mycoplasma* species, only three polymers have had their structure elucidated thus far. This relatively low rate of structural characterization may be attributable to the necessity of purifying a high quantity (approximately 1 mg) of material for structure analyses by HPLC and NMR, which could be technically challenging depending on the species, culture conditions and overall complexity of the exopolysaccharide structure (e.g., biofilms) (Table 2).

Clear identification of the pathways involved in the synthesis of galactan, β-(1→6)-glucopyranose and β-(1→2)-glucopyranose has been helpful *in silico* screening of other species for their potential to produce polysaccharides. However, for *M. pulmonis*, *M. genitalium* and *M. pneumoniae*, the EPS biosynthesis pathways have yet to be deciphered. In *M. pulmonis*, random transposon mutagenesis identified the role of two genes coding for ABC transporters, but failed to find the glycosyltransferase catalyzing the polymerization. This suggests that polymerization of the polysaccharides could be an essential function for mycoplasmas. Other mutations in genes involved in polysaccharide biosynthesis were shown to have an adverse effect on cell viability; for example, a mutation in the UDP galactofuranose mutase gene of *M. mycoides subsp. capri* reduced

**Table 2** List of *Mycoplasma* (sub)species producing exopolysaccharides.

| Species                  | Hosts  | Strains          | Culture conditions | Tools                          | Polysaccharides                        | Biosynthesis pathways | CPS/EPS | References                  |
|--------------------------|--------|------------------|--------------------|-------------------------------|----------------------------------------|-----------------------|---------|----------------------------|
| *M. pneumoniae*          | Human  | M129, UAB PO1    | Biofilm            | GC                            | Galactose, GlcNac                      | ND                    | ND      | EPS Simmons et al., 2013   |
|                          |        |                  |                    |                               | Galactose, GlcNac                      | ND                    | ND      | CPS Simmons et al., 2013   |
| *M. mycoides subsp. mycoides* | Bovine | V5               | Cell grown in complex medium | Biochemical and optical methods | Galactose β-(1→6)-galactofuranose Synthase CPS | ND                    | CPS     | Plackett and Buttery, 1958, 1964 |
|                          |        | Afadé            | Cell incubated in CMRL-medium | HPLC, NMR, MAb                | Galactose β-(1→6)-galactofuranose Synthase CPS/EPS | |          | Bertin et al., 2013, 2015   |
| *M. mycoides subsp. capri serovar capri* | Caprine | PG3T            | Cell grown in complex medium | HPLC, NMR | Glucose β-(1→6)-glucopyranose Synthase CPS/EPS | |          | Bertin et al., 2016       |
| *M. mycoides subsp. capri serovar LC* | Caprine | 95010           | Cell grown in complex medium | MAb | Galactose β-(1→6)-galactofuranose Synthase CPS/EPS | |          | Bertin et al., 2015       |
| *M. capricolum subsp. capricolum* | Caprine | 7714            | Cell grown in complex medium | MAb | Glucose β-(1→2)-glucopyranose Synthase CPS/EPS | |          | Bertin et al., 2015       |
| *M. capricolum subsp. capripneumoniae* | Caprine | Ambosha         | Cell grown in complex medium | MAb | Glucose β-(1→2)-glucopyranose Synthase CPS/EPS | |          | Bertin et al., 2015       |
| *M. leachi*              | Bovine | PG50T           | Cell incubated in CMRL-medium | HPLC, NMR | Glucose β-(1→2)-glucopyranose Synthase EPS | |          | Bertin et al., 2015       |
|                          |        | Cell grown in complex medium | MAb | Glucose β-(1→2)-glucopyranose | |          | | |
| *M. agalactiae*          | Caprine | 14628           | Cell grown in complex medium | HPLC, NMR, MAb | Glucose β-(1→6)-glucopyranose Synthase CPS | |          | Gaurivaud et al., 2016    |
| *M. feriruminatoris*     | Ibex   | 15568           | Cell grown in complex medium | HPLC, NMR, MAb | Glucose, galactose β-(1→6)-glucopyranose Synthase CPS | |          | Ambrosset al., 2017       |

ND, not determined; Mab, monoclonal antibody; HPLC, high pressure liquid chromatography; NMR, nuclear magnetic resonance; CPS, cell-linked polysaccharide; EPS, exopolysaccharide; GlcNac, N-acetylglucosamine; PNAG, Poly-N-acetylglucosamine; T, type strain; GC, gas chromatography.
in vitro produced once observed for cell-lysis events leading to membrane vesicles formation were with respect to their composition (Toyofuku et al., 2019). Explosive However, these vesicles differ from surface-budding EV with Bacillus[10 atm for cell-wall, the cell is lysed because of the high intracellular pressure peptidoglycan hydrolyzing enzyme. After the degradation of the “explosion” results from the expression of an autolysin, i.e., a described recently for Bacillus[2018]). Of all the putative virulence factors found in EV membranes, DnaK is one of the most abundant proteins (Gaurivaud et al., 2018) and this protein has also been detected in host cells (Zella et al., 2018) (see earlier). Secretion through EV and delivery into the host cells could be used by mycoplasmas that are devoid of other more classical secretion systems. Secretion of proteins through EV confers both protection of the cargo molecules against degradation and an efficient transport system able to deliver high concentrations of cargo molecules to the cells (Coelho and Casadevall, 2019; McMillan and Kuehn, 2021).

Bacterial EV could be involved in nutrient acquisition, as recently described for iron acquisition by EV of Mycobacterium tuberculosis and Pseudomonas (P.) aeruginosa (Prados-Rosales et al., 2014; Lin et al., 2017). These bacteria are able to scavenge the iron sequestered by EV, and because of their dissemination over long distances, EV are assumed to supply nutrients to bacteria localized at different infection sites. Given that nutrient binding proteins, such as those belonging to ABC transporter systems, have been identified in the EV membranes of mycoplasmas (Gaurivaud et al., 2018), EV could participate in nutrient acquisition, which is a crucial feature for these biosynthetically limited bacteria.

Gaps and Perspectives

Data on the biogenesis, composition and role of mycoplasmal EV are scarce. Despite the considerable efforts made to date, there is still a need to further optimize the purification of EV (Thery et al., 2018) and completely eliminate the small-sized mycoplasma cells observed in the purified material from some species (Gaurivaud et al., 2018). A second gap to address is to complete the characterization of the EV composition and, crucially, their cytoplasmic content. The presence of polypeptides, nucleic acids, DNA and RNA within EV has not been yet assessed. A method that can directly assess the presence of DNA or RNA inside EV has been proposed recently (Bitto et al., 2017).

Extracellular vesicles secretion is energetically expensive for bacteria (McMillan and Kuehn, 2021) and may even be more expensive for the small-sized (300–800 nm diameter) mycoplasmas (Razin et al., 1998), which produce EV of 30–170 nm diameter. This raises the question of the fitness burden that EV release might represent for mycoplasmas, which needs to be compensated for by beneficial roles of EV release. Remodeling mycoplasmas membrane by vesicle production could be a rapid mechanism to maintain membrane integrity and its adaptation to changing environments, as it is described for other bacteria (McMillan and Kuehn, 2021). Deciphering...
the cargo composition of EV, and an in-depth comparison of virulence factors in the vesicle membranes (Gaurivaud et al., 2018) with those of parental cells, would certainly help define these beneficial roles. Selective cargo packaging, i.e., preferential exclusion or selection of vesicle cargo, has already been demonstrated in enterotoxigenic *Escherichia coli* during stress (Orench-Rivera and Kuehn, 2021). EV produced by explosive-cell events [observed for *M. hyopneumoniae* biofilm in vitro (Raymond et al., 2018a)] carry different cargo than classical EV and may have different roles (Toyofuku et al., 2019; McMillan and Kuehn, 2021) such as release of "public goods" useful for the bacterial community inside the biofilm (Turnbull et al., 2016).

The in vitro use of cellular models to study EV release and cytotoxicity or their effect on immunity compared to mycoplasmas alone would bring further insights into their role. Similarly, experimental infection of animals could provide information about the potential long-distance dissemination of mycoplasmal EV (Stentz et al., 2018).

Extracellular vesicles-based vaccines could also hold promise for use in mycoplasmosis control as it has been shown for other bacterial diseases (Jiang et al., 2019; Behrens et al., 2021). However, the presence of proinflammatory lipoproteins in the mycoplasmal EV membrane and the yield rate and cost of *in vitro* EV production remain technical and economic bottlenecks, although they could be solved by expressing extracellular virulence factors within heterologous EV systems (Carvalho et al., 2019; Stentz et al., 2022).

### Other Components of the Releasome

In addition to the three main elements of the releasome (exoproteins, EPS, and EV), mycoplasmas can also release other molecules, including DNA and byproducts of mycoplasmal metabolism. Further insights into the biology of mycoplasmas came from the recent demonstration within *M. hyopneumoniae* of morphological variants called ‘large cell variants’ (LCV) with inherent membrane instability and hence a capacity to release their cytoplasmic content, notably extracellular DNA by cell lysis leading to the formation of ghost cells and to explosive cell events (Raymond et al., 2018a). As extracellular DNA is necessary for biofilm formation on abiotic surfaces, Raymond et al. proposed that mycoplasmas could be self-sufficient in producing this DNA through LCV lysis. The contribution of LCV cell lysis to the final composition of the releasome has yet to be further defined.

Two byproducts of mycoplasmal metabolism, hydrogen peroxide and hydrogen sulfide, have drawn attention because of their potential cytotoxicity. Hydrogen sulfide is produced during cysteine catabolism by cysteine desulphurase/desulphhydrase encoded by the *HapE* gene, which is found in many mycoplasmas (Grosshennig et al., 2016). Hydrogen peroxide is produced through glycerol metabolism by L-α-glycerophosphate oxidase or peroxide hydrogen NADH oxidase, and many mycoplasmas are able to produce it (Khan et al., 2005; Blotz and Stulke, 2017; Zhao et al., 2017). These two metabolites are considered virulence factors because of their capacity to damage their host cells (Blotz and Stulke, 2017). Hydrogen sulfide produced by *M. pneumoniae* has hemolytic activity (Grosshennig et al., 2016). Hydrogen peroxide, a known virulence factor of *Streptococcus pneumoniae* (Gonzales et al., 2021), may be a virulence factor in several *Mycoplasma* species (Pilo et al., 2005; Hames et al., 2009; Zhu et al., 2019). In addition, hydrogen peroxide could prevent growth of competing bacteria (Herrero et al., 2016), thus offering an advantage in niche colonization.

### CONCLUSION

Mycoplasmas actively release a wide variety of molecules and elements—from metabolites to proteins, polysaccharides, DNA and EV—into their environment. Not all these elements are associated with a known secretion system, but their common extracellular localization provides grounds for gathering them together under the general term of releasome. Besides molecules and elements actively released by living cells, cell lysis leading to formation of ghosts cells and explosive cells event could be a mechanism for generating a certain releasome in a biofilm context (Raymond et al., 2018a).

Characterization of the releasome of *Mycoplasma* spp. began with the first culture of a mycoplasma, in 1898. To parallel with other bacteria, the first extracellular elements searched for were toxins and other virulence factors. Despite the methodological bottlenecks of the time, proteases, lipases and nucleases in the extracellular environment were detected early on, but the corresponding secretion machineries and their substrates were not identified. With time, another difficulty has arisen, as most of the released elements or parts of them (for instance, the polysaccharide moiety of cell-linked galactan or the external region of membrane proteases) also have a cell-localized counterpart that could have a different function, highlighting the tight connection between the releasome and the surfaceome. EVs have an important role in the releasome as they can contain proteins, polysaccharides and DNA in a protected environment. The physical form (free vs. EV-associated) of various elements of the releasome may modify their role, as has been described for LPS-induced activation of the inflammasome in *P. aeruginosa* (Bitto et al., 2018).

Data collected for the purpose of this review show that the elements of the releasome are now recognized as playing important roles in nutrient acquisition, adhesion to and invasion of host cells, and immune system modulation and evasion. However, a better understanding of the global role and dynamics of the releasome hinges on studying the balance of its different components (proteins, polysaccharides, metabolites and EV) at a precise time point after infection of the host, in different host sites, in specific physiological states of mycoplasmas, including their intracellularity.

Further advances in deciphering the releasome of mycoplasmas will bring further knowledge and hypotheses about the interplay between mycoplasmas and their hosts and help to progress identification of new molecules involved in virulence or cytoplasmic or membrane molecules that have different roles once they are released from the cell. Such virulence factors are not included in current inactivated vaccines. Moreover, exoproteome modifications have been observed after *in vitro* serial passage (Zhang et al., 2021), which indicates that
the releasome of passage-attenuated vaccine strains may differ from that of virulent field strains. Ultimately, experiments are needed to assess the benefit of adding releasome components to current vaccines.

DEFINITIONS

Releasome: set of not cell-attached molecules (proteins, polysaccharides, DNA and metabolites) and elements (EV) released by a living cell into its extracellular environment, whatever the release/secretion mechanism, but excluding release by cell lysis and contamination by medium components. As opposed to the secretome, the machinery of secretion may be unknown.

Secretome: classically defined as the set of proteins and their corresponding secretion systems allowing translocation through the membrane from the inside to the outside of the cell. This implies that the secretion systems are known.

Exoprotein: a protein released by viable mycoplasmas into their environment. This excludes cell-attached proteins (surfacome).

Exoproteome: set of exoproteins secreted by a cell in a defined time and environment.

Extracellular vesicle (EV): nanosized, membranous spherical structure produced from viable cells by budding. EVs are composed of a part of the membrane and cytoplasm of the parental cell, but cargo selection means that their composition is not the same as the parental cell.

Cell-linked polysaccharide (CPS): polysaccharide covalently linked to the cell surface. The resulting polymer remains attached to the cell where it can form a capsule or a slime layer around the cells. CPS are purified from washed cells.

Exopolysaccharide (EPS): polysaccharide non-covalently linked to the cell surface and released free in the culture supernatant or within the host. Such polysaccharides are purified in vitro from a cell-free supernatant.

AUTHOR CONTRIBUTIONS

PG and FT conceptualized, wrote the first manuscript draft, and revised the manuscript. All authors have read and approved the final version of the manuscript.

ACKNOWLEDGMENTS

We would like to thank the many students who participated in laboratory experiments behind some of the data assembled for this review: Monika Gjorgieva, Khadija Berrouane, Victoria Mari, Quentin Granjon, Marie Guillot, Alexandre Chassard, Alexandre Villard, Clothilde Bertin, and Sarah Ganter. We are very grateful to Laure Beven for critically reading this manuscript.

REFERENCES

Adams, C., Pitzer, J., and Minion, F. C. (2005). In vivo expression analysis of the P97 and P102 paralog families of Mycoplasma hyopneumoniae. Infect. Immun. 73, 7784–7787. doi: 10.1128/IAI.73.11.7784-7787.2005

Adamu, J. Y., Wawegama, N. K., Kanci Condello, A., Marenda, M. S., Markham, P. F., Brownin, G. F., et al. (2020). Mycoplasma bovis membrane protein MiA is a multifunctional lipase with novel lipid and glycosaminoglycan binding activity. Infect. Immun. 88:e00945-19. doi: 10.1128/IAI.00945-19

Afshar, A. (1967). The growth of Mycoplasma bovigenitalium in cell cultures. J. Gen. Microbiol. 47, 103–110. doi: 10.1099/0021287-47-1-103

Allam, A. B., Brown, M. B., and Reyes, L. (2012). Disruption of the S41 peptidase gene in Mycoplasma mycoides capri impacts proteome profile, H2O(2) production, and sensitivity to heat shock. PLoS One 7:e51345. doi: 10.1371/journal.pone.0051345

Allam, A. B., Reyes, L., Assad-Garcia, N., Glass, J. I., and Brown, M. B. (2010). Enhancement of targeted homologous recombination in Mycoplasma mycoides subsp. capri by inclusion of heterologous recA. Appl. Environ. Microbiol. 76, 6951–6954. doi: 10.1128/AEM.00556-10

Ambroset, C., Pau-Roblot, C., Game, Y., Gaurivaud, P., and Tardy, F. (2017). Identification and characterization of Mycoplasma fermentarius sp. nov. strains isolated from Alpine ibex: a 4th species in the Mycoplasma mycoides cluster. In: Front. Microbiol. 8:939. doi: 10.3389/fmicb.2017.00939

Armengaud, J., Christie-Oleza, J. A., Clair, G., Malard, V., and Duport, C. (2012). Exoproteomics: exploring the world around biological systems. Expert Rev. Proteomics 9, 561–575. doi: 10.1586/epr.12.52

Askar, H., Chen, S., Hao, H., Yan, X., Ma, L., Liu, Y., et al. (2021). Immune evasion of Mycoplasma bovis. Pathogens 10:297. doi: 10.3390/pathogens10030297

Atkin, C. L., Wei, S., and Cole, B. C. (1994). The Mycoplasma arthritidis superantigen MAM: purification and identification of an active peptid. Infect. Immun. 62, 5367–5375. doi: 10.1128/iai.62.12.5367-5375.1994

Behrens, F., Funk-Hilsdorf, T. C., Kuebler, W. M., and Simmons, S. (2021). Bacterial membrane vesicles in pneumonia: from mediators of virulence to innovative vaccine candidates. Int. J. Mol. Sci. 22:3858. doi: 10.3390/ijms22083858

Bendjennat, M., Blanchard, A., Loutfi, M., Montagnier, L., and Bahraoui, E. (1997). Purification and characterization of Mycoplasma penetrans Ca2+/Mg2+-dependent endonuclease. J. Bacteriol. 179, 2210–2220. doi: 10.1128/jb.179.7.2210-2220.1997

Bendjennat, M., Blanchard, A., Loutfi, M., Montagnier, L., and Bahraoui, E. (1999). Role of Mycoplasma penetrans endonuclease P40 as a potential pathogenic determinant. Infect. Immun. 67, 4456–4462. doi: 10.1128/IAI.67.9.4456-4462.1999

Benediti, F., Cocchi, F., Latinovic, O. S., Curreli, S., Krishnan, S., Munawar, A., et al. (2020). Role of Mycoplasma chaperone DnaK in cellular transformation. Int. J. Mol. Sci. 21:1311. doi: 10.3390/ijms21041311

Berry, I. J., Jarocki, V. M., Tacchi, J. L., Raymond, B. B. A., Widjaja, M., Padula, M. P., et al. (2017). N-terminomics identifies widespread endopeptidolysis and novel methionine excision in a genome-reduced bacterial pathogen. Sci. Rep. 7:11063. doi: 10.1038/s41598-017-11296-9

Bertin, C., Pau-Roblot, C., Courtois, J., Manso-Silvan, L., Tardy, F., Pournarat, F., et al. (2015). Highly dynamic genomic loci drive the synthesis of two types of capsular or secreted polysaccharides within the Mycoplasma mycoides cluster. Appl. Environ. Microbiol. 81, 676–687. doi: 10.1128/AEM.02892-14

Bertin, C., Pau-Roblot, C., Courtois, J., Manso-Silvan, L., Thiaucourt, F., Tardy, F., et al. (2013). Characterization of free exopolysaccharides secreted by Mycoplasma mycoides subsp. mycoides. PLoS One 8:e68373. doi: 10.1371/journal.pone.0068373

Bitto, N. J., Baker, P. J., Dowling, J. K., Wray-McCann, G., De Paoli, A., Tran, L. S., et al. (2018). Membrane vesicles from Pseudomonas aeruginosa activate the noncanonical inflammasome through caspase-5 in human monocytes. Immunol. Cell Biol. 96, 1120–1130. doi: 10.1111/icb.12190

Bitto, N. J., Chapman, R., Pidot, S., Costin, A., Lo, C., Choi, J., et al. (2017). Bacterial membrane vesicles transport their DNA cargo into host cells. Sci. Rep. 7:7072. doi: 10.1038/s41598-017-07288-4

Blotz, C., and Stulke, J. (2017). Glycerol metabolism and its implication in virulence in Mycoplasma. FEMS Microbiol. Rev. 41, 640–652. doi: 10.1093/femsre/fux033
Gaurivaud and Tardy The Releasome of Mycoplasmas

Houot, L., Chang, S., Pickering, B. S., Absalon, C., and Watnick, P. I. (2010). *J. Bacteriol.* 192, 3055–3067. doi: 10.1128/JB.00213-10

Hudson, J. R., Buttery, S., and Cottew, G. S. (1967). Investigations into the influence of the galactan of *Mycoplasma mycoides* on experimental infection with that organism. *J. Pathol. Bacteriol.* 94, 257–273. doi: 10.1002/path.1700940204

Hummeler, K., Tommassini, N., and Hayflick, L. (1965). Ultrastructure of a strain producing high levels of H2O2. *Scand. J. Immunol.* 10, 91–119. doi: 10.1111/j.1365-2567.1965.tb00744.x

Hwang, M. H., Damte, D., Cho, M. H., Kim, Y. H., and Park, S. C. (2010). Optimization of culture media of pathogenic *Mycoplasma hyopneumoniae* by a response surface methodology. *J. Vet. Sci.* 11, 327–332. doi: 10.4162/jvs.2010.11.4.327

Jarocki, V. M., Raymond, B. B. A., Tacchi, J. L., Padula, M. P., and Djordjevic, S. P. (2019). *Mycoplasma hyopneumoniae* surface-associated proteases cleave bradykinin, substance P, neurokinin A and neuropeptide Y. *Sci. Rep.* 9:14585. doi: 10.1038/s41598-019-51116-w

Jarocki, V. M., Santos, J., Tacchi, J. L., Raymond, B. B., Deutscher, A. T., Jenkins, P. D., Padula, M. P., and Djordjevic, S. P. (2019). *Mycoplasma hyopneumoniae* surface-associated proteases cleave bradykinin, substance P, neurokinin A and neuropeptide Y. *Sci. Rep.* 9:14585. doi: 10.1038/s41598-019-51116-w

Jiang, L., Schinkel, M., van Essen, M., and Schiffelers, R. M. (2019). Bacterial membrane vesicles as promising vaccine candidates. *Microbiol. Spectr.* 3. doi: 10.1128/microbiolspec.MB-0011-2014

Lin, J., Zhang, W., Cheng, J., Yang, X., Zhu, K., Wang, Y., et al. (2017). A *Pseudomonas* T6SS effector recruits PQS-containing outer membrane vesicles for iron acquisition. *Nat. Commun.* 8:14888. doi: 10.1038/ncomms14888

Lloret, E., Tomas, J. M., and Bengoechea, J. A. (2008). *Capsule polysaccharide is a bacterial decoy for antimicrobial peptides*. *Microbiology* (Reading) 154(Pt.12), 3877–3886. doi: 10.1099/mic.0.023301-0

Lloyd, L. C. (1966). Tissue necrosis produced by *Mycoplasma mycoides* isolated from human leukemia. *J. Bacteriol.* 90, 517–523. doi: 10.1128/JB.90.2.517-523.1965

Löbbert, E., Tomas, J. M., and Bengoechea, J. A. (2008). *Capsule polysaccharide is a bacterial decoy for antimicrobial peptides*. *Microbiology* (Reading) 154(Pt.12), 3877–3886. doi: 10.1099/mic.0.023301-0

Lönn, S. P. (2019). *Pathogens* 10:119. doi: 10.3390/pathogens10020119

Machado, L., Paes, J. A., Souza Dos Santos, P., and Ferreira, H. B. (2020). Evidences of differential endoproteolytic processing on the surfaces of *Mycoplasma hyopneumoniae* and *Mycoplasma flocculare*. *Microb. Pathog.* 140:103958. doi: 10.1016/j.micpath.2019.103958.

Madsen, M. L., Nettleton, D., Thacker, E. L., and Minion, F. C. (2006). Transcriptional profiling of *Mycoplasma hyopneumoniae* during iron depletion using microarrays. *Microbiology* (Reading) 152(Pt.4), 937–944. doi: 10.1099/mic.0.28674-0

Marois, C., Le Carrou, J., Kojic, M., and Gautier-Bouchardon, A. V. (2006). Isolation of *Mycoplasma hyopneumoniae* from different sampling sites in experimentally infected and contact SPF piglets. *Vet. Microbiol.* 120, 96–104. doi: 10.1016/j.vetmicro.2006.10.015

Martinez-Torro, C., Torres-Puig, S., Monge, M., Sanchez-Alba, L., Gonzalez-Martin, M., Marcos-Silva, M., et al. (2020). Transcriptional response to metal starvation in the emerging pathogen *Mycoplasma genitalium* is mediated by Fur-dependent and -independent regulatory pathways. *Emerg. Microbes Infect.* 9, 5–19. doi: 10.1002/22217519.1700762

McGowan, C. L., Popov, V. L., and Pyles, R. B. (2009). Intracellular *Mycoplasma genitalium* infection of human vaginal and cervical epithelial cells elicits distinct patterns of inflammatory cytokine secretion and provides a possible survival niche against macrophage-mediated killing. *BMC Microbiol.* 9:139. doi: 10.1186/1471-2180-9-139

McMillan, H. M., and Kuehn, M. J. (2021). The extracellular vesicle generation paradox: a bacterial point of view. *EMBO J.* 40:e108174. doi: 10.15252/embj.202108174

Minion, F. C., Jarvill-Taylor, K. J., Billings, D. E., and Tigges, E. (1993). Membrane-Paradox: a bacterial point of view. *EMBO J.* 12:3897–3906. doi: 10.1002/j.1460-2075.1993.tb03215.x

Minion, F. C., Jarvill-Taylor, K. J., Billings, D. E., and Tigges, E. (1993). Membrane-Paradox: a bacterial point of view. *EMBO J.* 12:3897–3906. doi: 10.1002/j.1460-2075.1993.tb03215.x

Monteiro, R., Chafsey, I., Ageorges, V., Leroy, S., Chambon, C., Hebraud, M., et al. (2019). *J. Immunol.* 202, 154(Pt. 12), 232:104025. doi: 10.3389/fimmu.2019.02085

Mu, H. H., Sawitzke, A. D., and Cole, B. C. (2000). Modulation of cytokine profiles by *Mycoplasma arthritidis* isolated from human leukemia. *J. Proteomics* 192, 53–62. doi: 10.1016/j.jprot.2018.08.018

Ni, P., Zhang, Y., Li, X., Zhou, W., Li, X., Jiang, F., et al. (2019). *Mycoplasma hyopneumoniae* Mhp597 is a cytotoxicity, inflammation and immunosuppression associated nuclease. *Vet. Microbiol.* 235, 53–62. doi: 10.1016/j.vetmic.2019.05.011

Lalitennakki, M., Edelman, S., and Korhonen, T. K. (2005). Bacterial metastasis: the host plasminogen system in bacterial invasion. *Trends Microbiol.* 13, 79–85. doi: 10.1016/j.tim.2004.12.003

Le Carrou, J., Laurentie, M., Kobisch, M., and Gautier-Bouchardon, A. V. (2006). Persistence of *Mycoplasma hyopneumoniae* in experimentally infected pigs after marbofloxacin treatment and detection of mutations in the parC gene. *Antimicrob. Agents Chemother.* 50, 1959–1966. doi: 10.1128/AAC.01527-05

Leal Zimmer, F. M. A., Paes, J. A., Zaha, A., and Ferreira, H. B. (2020). Pathogenicity and virulence of *Mycoplasma hyopneumoniae*. *Virology* 11, 1600–1622. doi: 10.1016/j.virome.2020.1842659

Leal Zimmer, F., Paludo, G. P., Moura, H., Barr, J. R., and Ferreira, H. B. (2019). Differential secretome profiling of a swine tractal cell line infected with mycoplasmas of the swine respiratory tract. *J. Proteomics* 192, 147–159. doi: 10.1016/j.jprot.2018.08.018

Nguyen, M. T., Peisl, L., Barletta, F., Lugman, A., and Gotz, F. (2018). Toll-like receptor 2 and lipoprotein-like lipoproteins enhance *Staphylococcus aureus* like receptor 2 and lipoprotein-like lipoproteins enhance...
invasion in epithelial cells. *Infect. Immun.* 86:e00343-18. doi: 10.1128/IAI.00343-18

Nocard, and Roux (1898). The microbe of pleuropneumonia. *Rev. Infect. Dis.* 12, 354–358. doi: 10.1093/clinids/12.3.354

Olaya-Abril, A., Gonzalez-Reyes, J. A., and Rodriguez-Ortega, M. J. (2021). Approaching in vivo models of pneumococci-host interaction: insights into surface proteins, capsule production, and extracellular vesicles. *Pathogens* 10:1098. doi: 10.3390/pathogens10091098

Oren-Rivera, N., and Kuehn, M. J. (2021). Differential packaging into outer membrane vesicles upon oxidative stress reveals a general mechanism for cargo selectivity. *Front. Microbiol.* 12:561863. doi: 10.3389/fmicb.2021.561863

Paes, J. A., Lorenzatto, K. R., de Moraes, S. N., Moura, H., Barr, J. R., and Ferreira, H. B. (2017). Secretomes of *Mycoplasma hypomagnesiae* and *Mycoplasma flocculare* reveal differences associated to pathogenesis. *J. Proteomics* 154, 69–77. doi: 10.1016/j.jprot.2016.12.002

Pilo, P., Veli, E. M., Peterhans, E., Bonvín-Klotz, L., Stoffel, M. H., Dobbelaae, d., et al. (2005). A metabolic enzyme as a primary virulence factor of *Mycoplasmacyoides subsp. mycoides* small colony. *J. Bacteriol.* 187, 6824–6831. doi: 10.1128/JB.187.19.6824-6831.2005

Plackett, P., and Buttery, S. H. (1958). A galactan from *Mycoplasma mycoides*. *Nature* 182, 1236–1237. doi: 10.1038/1821236a0

Plackett, P., and Buttery, S. H. (1964). A galactofuranose disaccharide from the cell envelope of *Mycoplasma mycoides*. *Biochem. J.* 90, 201–205. doi: 10.1042/bj0900201

Plackett, P., Buttery, S., and Cottew, G. (1963). “Carbohydrates of some mycoplasma-like organisms.” In *Progress in Microbiology VIII*, ed. N. E. Gibbons (Toronto, ON: University of Toronto Press), 533.

Prados-Rosales, R., Weinrick, B. C., Pique, D. G., Jacobs, W. R. Jr., Casadevall, A., Plackett, P., and Buttery, S., and Cottew, G. (1963). “Carbohydrates of some mycoplasma-like organisms.” In *Progress in Microbiology VIII*, ed. N. E. Gibbons (Toronto, ON: University of Toronto Press), 533.

Raymond, B. B. A., Turnbull, L., Jenkins, C., Madhkoor, R., Schleicher, I., Vozza, N., Hegermann, J., Miller, R. A., et al. (2013). MHJ_0125 is an M42 glutamyl aminopeptidase that moonlights extracellular and wall polysaccharides. *Mycobacterium Tuberculosis* 62.4.1094-1156.1998

Raymond, B. B. A., Turnbull, L., Whitchurch, C. B., and Djordjevic, M. S., et al. (2012). Post-translational processing targets functionally diverse proteins in extracellular and wall polysaccharides. *Microbiol. Spectr.* 14, 81–94. doi: 10.1128/microbiolspec.GPP3-0.064782-0

Sharma, S., Tivendale, K. A., Markham, P. F., and Browning, G. F. (2015). Disruption of the membrane nuclease gene (MOBVG45_0215) of *Mycoplasma bovis* greatly reduces cellular nuclease activity. *J. Bacteriol.* 197, 1549–1558. doi: 10.1128/JB.00334-15

Sharma, S., Dhasmana, N., Dubey, N., Kumar, N., Gangwal, A., Gupta, M., et al. (2017). Virulence factors selectivity. *Indian J. Microbiol.* 57, 1–10. doi: 10.1007/s12088-016-0625-1

Sharma, S., Markham, P. F., and Browning, G. F. (2014). Genes found essential in other mycoplasmas are dispensable in *Mycoplasma bovis*. *PLoS One* 9:e97100. doi: 10.1371/journal.pone.0097100

Sieg, C., and Rudel, T. (2015). Modulation of p53 during bacterial infections. *Nat. Rev. Microbiol.* 13, 741–748. doi: 10.1038/nrmicro3537

Staats, C. C., Boldo, J. T., Broetto, L., Vainstein, M. H., and Schrank, A. (2007). Comparative genome analysis of proteases, oligopeptide uptake and secretion systems in *Mycoplasma spp*. *Genet. Mol. Biol.* 30, 225–229.

Stenzel, R. J., Carvalho, A. L., Jones, E. J., and Carding, S. R. (2018). Fantastic voyage: the journey of intestinal microbiota-derived microvesicles through the body. *Microbiol. Soc. Trans.* 6, 1021–1027. doi: 10.1099/mst.000748-0

Stenzel, R., Miquel-Clopés, A., and Carding, S. R. (2022). Production, isolation, and characterization of bioengineered bacterial extracellular membrane vesicles derived from *Bacteroides thetaiotaomicron* and their use in vaccine development. *Methods Mol. Biol.* 2414, 171–190. doi: 10.1007/978-1-071-1900-1_11

Sudhakar, B. N., and Torres, V. J. (2019). *Staphylococcus aureus* secreted toxins and extracellular enzymes. *Microbiol. Spectr.* 7. doi: 10.1128/microbiolspec.GPP3-0039-2018

Sutherland, I. W. (1972). Bacterial exopolysaccharides. *Adv. Microb. Physiol.* 8, 143–213. doi: 10.1128/microbiolspec.GPP3-0039-2018

Thery, C., Witwer, K. W., Akawa, E., Alcaraz, M. J., Anderson, J. D., et al. (2013). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J. Extracell. Vesicles* 7:1535750. doi: 10.1080/20013078.2018.1535750
The secretome of Mycoplasma pneumoniae non-phagocytic factors. FEMS Microbiol. Lett. 233, 241–246. doi: 10.1016/j.femsle.2004.02.016

Yiwen, C., Yueyue, W., Lianmei, Q., Cuiming, Z., and Xiaoxing, Y. (2021). Infection strategies of mycoplasmas: unraveling the panoply of virulence factors. Virulence 12, 788–817. doi: 10.1007/s12258-021-18898-3

Yus, E., Maier, T., Michalodimitrakis, K., van Noort, V., Yamada, T., Chen, W. H., et al. (2009). Impact of genome reduction on bacterial metabolism and its regulation. Science 326, 1263–1268. doi: 10.1126/science.1177263

Zella, D., Curelli, S., Benedetti, F., Krishnan, S., Cocchi, F., Latinioc, O. S., et al. (2018). Mycoplasma promotes malignant transformation in vivo, and its DnaK, a bacterial chaperone protein, has broad oncogenic properties. Proc. Natl. Acad. Sci. U.S.A. 115, E12005–E12014. doi: 10.1073/pnas.1815660115

Zhang, H., Hu, G., Lu, D., Zhao, G., Zhang, Y., Zubair, M., et al. (2021). Comparative secretome analyses of Mycoplasma bovis virulent and attenuated strains revealed MboP0145 as a promising diagnostic biomarker. Front. Vet. Sci. 8:666769. doi: 10.3389/fvets.2021.666769

Zhang, H., Zhao, G., Guo, Y., Menghwar, H., Chen, Y., Chen, H., et al. (2016). Mycoplasma bovis MBOV_RS02825 encodes a secretory nuclease associated with cytotoxicity. Int. J. Mol. Sci. 17:628. doi: 10.3390/ijms17060628

Zhao, G., Zhang, H., Chen, X., Zhu, X., Guo, Y., He, C., et al. (2017). Mycoplasma bovis NADH oxidase functions as both a NADH oxidizing and O2 reducing enzyme and an adhesin. Sci. Rep. 7:44. doi: 10.1038/s41598-017-00121-y

Zhao, G., Zhu, X., Zhang, H., Chen, Y., Schieck, E., Hu, C., et al. (2021). Novel secreted protein of Mycoplasma bovis MboP280 induces macrophage apoptosis through CRPYB. Front. Immunol. 12:619362. doi: 10.3389/fimmu.2021.619362

Zhu, X., Dordet-Frisoni, E., Gillard, L., Ba, A., Hygonen, M. C., Sagne, E., et al. (2019). Extracellular DNA: a nutritional trigger of Mycoplasma bovis cytotoxicity. Front. Microbiol. 10:2753. doi: 10.3389/fmicb.2019.02753

Zubair, M., Khan, F. A., Menghwar, H., Faisal, M., Ashraf, M., Zubair, M., et al. (2020a). Progresses on bacterial secretomes enlighten research on Mycoplasma secretome. Microb. Pathog. 143:104160. doi: 10.1016/j.micpath.2020.104160

Zubair, M., Muhamed, S. A., Khan, F. A., Zhao, G., Menghwar, H., Faisal, M., et al. (2020b). Identification of 60 secreted proteins for Mycoplasma bovis with secretome assay. Microb. Pathog. 143:104135. doi: 10.1016/j.micpath.2020.104135

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer GB is currently organizing a Research Topic with the author FT.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Gaurivaud and Tardy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.